Therefore, this study discovered that glutamine flux increased the sensitivity to DHODH suppression which leads to synthetic lethality in PTEN-deficient cells, and suggested DHODH could be a potential therapy for PTEN-deficient cancer patients. This evidence concerns the gene DHODH and cancer.